Abediterol, a novel long-acting β2-agonist: Bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
Số trang: 13
Loại file: pdf
Dung lượng: 655.79 KB
Lượt xem: 3
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD.
Nội dung trích xuất từ tài liệu:
Abediterol, a novel long-acting β2-agonist: Bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
Nội dung trích xuất từ tài liệu:
Abediterol, a novel long-acting β2-agonist: Bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
Tìm kiếm theo từ khóa liên quan:
BMC Pulmonary Medicine Chronic respiratory disease β2-agonist Anti-inflammatory agent Chronic obstructive pulmonary diseaseTài liệu liên quan:
-
Clinical impact of cardiovascular disease on patients with bronchiectasis
7 trang 23 0 0 -
7 trang 23 0 0
-
8 trang 22 0 0
-
10 trang 20 0 0
-
9 trang 20 0 0
-
6 trang 19 0 0
-
9 trang 19 0 0
-
Disability-adjusted life years associated with population ageing in China, 1990- 2017
10 trang 18 0 0 -
Efect of periodontal therapy on COPD outcomes: A systematic review
16 trang 17 0 0 -
11 trang 17 0 0